Taken together, these observations suggest that high ITGB3 expression is part of a high-risk AML cell phenotype, also characterized by differences with regard to AML cell trafficking (i.e., lower peripheral blood blast count) as well as a different influence on the persisting normal hematopoiesis (i.e., higher levels of circulating platelets) compared with other patients. The gene discussed is ITGB3; the disease is acute myeloid leukemia.